$BMY (Bristol-Myers Squibb Company)

$BMY {{ '2016-06-16T09:14:20+0000' | timeago}} • SEC

$BMY's 1Q16 revenue grew 9% versus 1Q15 due to higher Opdivo, Eliquis and Daklinza product sales. US and Europe revenue rose in the quarter, mainly due to higher demand for Opdivo and Eliquis. Decrease in Rest of the World revenue was driven by lower demand due to increased competition for the Hepatitis C Franchise in Japan.

$BMY {{ '2017-07-27T12:44:31+0000' | timeago}} • Infographic

$BMY Bristol-Myers Squibb Co Earnings AlphaGraphics: Q2 2017 highlights

$BMY {{ '2017-07-27T11:32:39+0000' | timeago}} • Announcement

$BMY updated its FY17 GAAP EPS guidance range to $2.66-2.76 and raised the lower end of its non-GAAP EPS guidance range to $2.90-3.00, as the pharma giant posted 2Q17 results.

$BMY {{ '2017-07-27T11:30:29+0000' | timeago}} • Announcement

As $BMY posted its 2Q17 results, it also announced that the European Commission (EC) approved its drug ORENCIA alone or in combination with methotrexate for the treatment of active Psoriatic Arthritis in certain adult patients.

$BMY {{ '2017-07-27T11:28:03+0000' | timeago}} • Announcement

A 31% surge in R&D expenses of $1.7Bil in 2Q17 saw $BMY's net attributable earnings slumping 24% to $916MM, even as revenue rose 6% to $5.1Bil. Diluted EPS slipped 19% to $0.56, while non-GAAP diluted EPS rose 7% to $0.74.

$BMY {{ '2017-07-25T15:05:20+0000' | timeago}} • Announcement

The FDA has accepted $BMY's supplemental Biologics License Applications to update Opdivo dosing to include 480 mg infused over 30 minutes every four weeks for all currently approved monotherapy indications. The applications are under review with an action date of March 5, 2018. Opdivo has become important treatment option across multiple cancers.

$BMY {{ '2017-07-24T16:32:02+0000' | timeago}} • Announcement

$BMY said the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.

$BMY {{ '2017-07-10T11:35:22+0000' | timeago}} • Announcement

$BMY said the FDA accepted its supplemental New Drug Application (sNDA) to include an indication for Sprycel (dasatinib) to treat children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia, as well as a powder for oral suspension formulation of Sprycel.

$BMY {{ '2017-06-26T11:44:11+0000' | timeago}} • Announcement

$BMY said, in its Phase 3 study, Empliciti plus lenalidomide/dexamethasone continued to demonstrate efficacy in patients with plasma cell cancer, compared to patients treated with lenalidomide/dexamethasone alone. The combination therapy demonstrated a sustained reduction in risk of progression/death of 29%.

$BMY {{ '2017-06-21T11:54:13+0000' | timeago}} • Announcement

$BMY announced expiration on June 20 of its cash tender offer for any and all of certain of its outstanding debt securities. About $337MM of the notes were validly tendered and not validly withdrawn on or prior to June 20, 2017, and an additional $106,000 of the notes had been submitted pursuant to a Notice of Guaranteed Delivery.

$SGEN {{ '2017-06-15T12:21:22+0000' | timeago}} • Announcement

Pharma firms $SGEN and $BMY presented an interim analysis from the phase 1/2 clinical trial of  lymphoma drugs Adcetris and Opdivo in relapsed or refractory classical Hodgkin lymphoma, at the International Conference on Malignant Lymphoma in Switzerland. The drugs have not been approved, in combination, for the condition or for other indications.

$BMY {{ '2017-06-14T13:11:26+0000' | timeago}} • Announcement

$BMY commenced a cash tender offer for any and all of its 5.875% Notes due 2036, 6.125% Notes due 2038 and 6.875% Debentures due 2097. The expiration date of the tender offer is June 20, 2017, unless extended or earlier terminated.

$BMY {{ '2017-06-13T20:19:24+0000' | timeago}} • Announcement

$BMY's BoD declared a quarterly dividend of $0.50 per share on the $2 Convertible Preferred Stock, payable September 1, 2017 to stockholders of record on August 8, 2017.

$BMY {{ '2017-06-13T20:19:07+0000' | timeago}} • Announcement

$BMY's BoD declared a quarterly dividend of $0.39 per share on its $0.10 par value common stock. The next quarterly dividend will be payable on August 1, 2017, to stockholders of record on July 7, 2017.

$BMY {{ '2017-06-12T11:03:08+0000' | timeago}} • Announcement

Pharma firm $BMY is recalling one lot of Eliquis 5 mg tablets, indicated for stroke and blood clot, following a customer complaint that a bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets. The lot was distributed in the US to wholesalers and retail pharmacies in February 2017.

$BMY {{ '2017-04-27T15:40:46+0000' | timeago}} • Webcast

$BMY said that with respect to the patent life for Eliquis in major markets, the company's Composition of Matter patent expires in Feb. 2023. Additionally, the company also has a pending request for restoration of patent terms which goes until Nov. 2026.

$BMY {{ '2017-04-27T14:13:29+0000' | timeago}} • Announcement

$BMY now sees FY17 GAAP EPS at $2.72-2.87 and non-GAAP EPS at $2.85-3.00. Worldwide revenues are expected to rise in the mid-single digits, with research and development expenses increasing in the high-teens digit range. An effective tax rate of approximately 22% is estimated for the year.

$BMY {{ '2017-04-27T14:05:43+0000' | timeago}} • Announcement

Sales for key products Opdivo and Eliquis helped the net revenues of $BMY rise 12% to $4.9Bil in 1Q17, as earnings saw a 32% jump to $0.94 per diluted share. Net attributable earnings rose to $1.57Bil from $1.20Bil a year ago. U.S. revenues increased 8% to $2.7Bil in the quarter, while international revenues rose 18%.

$BMY {{ '2017-03-08T18:27:37+0000' | timeago}} • Announcement

$BMY has appointed Dr. Thomas J. Lynch, Jr. as EVP and Chief Scientific Officer, effective March 16, 2017. He succeeds Dr. Francis Cuss who will retire from the company. Dr. Lynch will step down from the Board of Directors of $BMY, effective March 15, 2017.

$BMY {{ '2017-03-02T21:55:05+0000' | timeago}} • Announcement

$BMY BoD also declared a quarterly dividend of $0.50 per share on the $2 Convertible Preferred Stock of the corporation, payable June 1, 2017 to stockholders of record at the close of business on May 9, 2017.

$BMY {{ '2017-03-02T21:54:26+0000' | timeago}} • Announcement

$BMY BoD declared a quarterly dividend of $0.39 per share on the $0.10 par value common stock of the corporation. The next quarterly dividend will be payable on May 1, 2017, to stockholders of record at the close of business on April 7, 2017.

Recent Transcripts

GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
ARRY (Array BioPharma Inc.)
Wednesday, May 10 2017 - 1:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
OPK (Opko Health, Inc.)
Tuesday, May 9 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
ARQL (ArQule Inc.)
Wednesday, May 3 2017 - 1:00pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
EXEL (Exelixis, Inc.)
Monday, May 1 2017 - 9:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, April 27 2017 - 2:00pm
ABBV (AbbVie Inc.)
Thursday, April 27 2017 - 1:00pm
CELG (Celgene Corporation)
Thursday, April 27 2017 - 1:00pm

AlphaGraphics you may like